Cannatrek to supply medicinal cannabis products to LYPHE Group to support Project TWENTY21

Australian seed-to-patient medicinal cannabis producer Cannatrek today announced it will supply medicinal cannabis products to LYPHE Group in support of Project TWENTY21, Europe’s first and largest national medical cannabis registry.

Project TWENTY21 will provide medical cannabis to 20,000 patients around the UK. The patients will have multiple conditions and diagnoses, including anxiety, chronic pain, epilepsy, multiple sclerosis, post-traumatic stress disorder, substance use disorder and Tourette’s Syndrome.

Project TWENTY21 is a patient registry which aims to help patients get access to medical cannabis while simultaneously gathering valuable evidence to the efficacy of medicinal cannabis products.

The aim of the scheme is to recruit up to 20,000 patients by the end of 2021. This would make the project the largest of its kind in Europe. Patients enrolling in the registry will be able to access to different medicinal cannabis products at a subsidized cost for the duration of the scheme.

Cannatrek will supply medicinal cannabis flowers for the project via LYPHE Group (Astral Health UK). Cannatrek announced in October that it had secured a key export supply agreement to LYPHE Group/Astral Health.

Cannatrek’s medicinal cannabis flowers will be crushed and inhaled via a vaporizer.

Tommy Huppert, Cannatrek CEO, said Cannatrek’s products will be among the first used in the trial, and will be the first locally produced Australian grown herbal cannabis ever exported into the UK.

“For us it opens up international trade pathways in what is still a nascent industry,” he said. “Project TWENTY21, with 20,000 patients, represents a very big study and will produce lots of valuable data for Cannatrek and for the industry. Crucially for us, Cannatrek is an important part of the supply chain for this study. Supply chains are being created very rapidly worldwide and we want to be front and centre of them.”

Chris Ashton, Chief Commercial Officer at LYPHE Group, said: “Project T21 is an incredibly important study in the UK and presents a great opportunity for the industry to demonstrate with valuable data the effectiveness and safety of using medical cannabis. It’s great to the have the support of Cannatrek, as a valued supplier to LYPHE Group, recognizing and supporting the study and helping so many patients. This will go a long way to ensuring that we have a continuous and high-quality supply chain ensuring the continued success of the Project TWENTY21 study.”